Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Future Growth Projections For The Carcinoid Tumor Market Size?

In the past few years, the market size for carcinoid tumors has witnessed notable expansion. It is projected to increase from $1.61 billion in 2024 to $1.77 billion in 2025, yielding a compound annual growth rate (CAGR) of 10.4%. This growth in the historic timeline can be credited to factors such as an elevated incidence rate of neuroendocrine tumors, heightened awareness about rare cancers, enhancements in healthcare infrastructures, accessibility to targeted therapies, and the broadening scope of clinical trials to explore innovative treatment alternatives.

In the forthcoming years, the market size for carcinoid tumors is anticipated to experience significant growth, projected to reach $2.62 billion in 2029 with a compound annual growth rate (CAGR) of 10.3%. Factors propelling growth during this period include the escalating demand for customized medication, a heightened emphasis on early diagnosis and detection, a surge in the preference for less invasive surgical procedures, expanded investigation into innovative treatments, and more frequent utilization of molecular targeted therapies. Standout trends for this period encompass the incorporation of artificial intelligence and machine learning into diagnostic processes, a lean towards combination therapies, advancements in telemedicine and remote patient monitoring, a focus on patient-oriented care, and collaborative research undertakings.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp

Which Demand Drivers Are Strengthening The Carcinoid Tumor Market?

The expansion of the carcinoid tumor market is set to be fueled by the escalation in the obese population. This demographic is made up of individuals with a body mass index (BMI) of 30 or more, showing an extreme accumulation of body fat. The rise in obesity rates is credited to factors like unhealthy eating patterns, sedentary behavior, a dearth of physical movement, and a surge in the intake of high-calorie, processed foods. Obesity can lead to the development of carcinoid tumors by inducing chronic inflammation, insulin resistance, and an enhanced secretion of growth factors that aid in tumor growth. For example, in September 2023, it was reported by the Centers for Disease Control and Prevention, a government agency based in the US, that in 2022, the rate of adult obesity was 35% or more in 22 states, a rise from 19 states the previous year, in 2021. Thus, the escalating obese population is steering the carcinoid tumor market’s growth.

What Segmentation Insights Are Provided In The Carcinoid Tumor Market Research?

The carcinoid tumormarket covered in this report is segmented –

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Lung Neuroendocrine Tumor; Other Disease Types

2) By Treatment: Octreotide; Lanreotide; Telotristat ethyl; Capecitabine (Xeloda); 5-Fluorouracil (5-FU); Doxorubicin (Adriamycin); Etoposide (VP-16); Dacarbazine (DTIC); Streptozocin; Other Treatments

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By Distribution Channel: Online Channel; Offline Channel

5) By End User: Hospital And Clinics; Academic Institutions; Research Organizations

Subsegments:

1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors; Appendiceal Neuroendocrine Tumors

2) By Pancreatic Neuroendocrine Tumor: Insulinoma; Non-insulinoma; Glucagonoma

3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors; Atypical Carcinoid Tumors

4) By Other Disease Types: Thymic Neuroendocrine Tumors; Ovarian Neuroendocrine Tumors

Which Market Trends Are Expected To Define The Future Of The Carcinoid Tumor Market?

Leading firms in the carcinoid tumor market are concentrating on developing advanced diagnostic technologies to amplify early detection and treatment efficiency. This includes the full-scale automation of the chromogranin A (CgA) test, which is used as a diagnostic tool to evaluate the presence of chromogranin A, often linked with neuroendocrine and carcinoid tumors. In the month of October 2023, Thermo Fisher Scientific Inc., an American biotechnology research corporation, was granted FDA approval for its invention of the Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This is recognized as the first FDA-authorized Chromogranin A (CgA) test, and the sole automated immunoassay used globally for monitoring tumor growth in patients with gastroenteropancreatic neuroendocrine tumor (GEP-NET). Engineered to calculate the CgA levels in human serum, the test provides laboratories and cancer centers with the means to monitor tumor evolution and evaluate the success of treatments. It enhances lab productivity and offers improved interpretation of results by substituting manually conducted lab tests. The Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, which employs TRACE technology, is used for the test and delivers accurate outcomes within 30 minutes.

Which Firms Are Driving Innovation Within The Carcinoid Tumor Market?

Major companies operating in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., Dauntless Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Carcinoid Tumor Market?

North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21127&type=smp

Browse Through More Reports Similar to the Global Carcinoid Tumor Market 2025, By The Business Research Company

Cancer Tumor Profiling Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Circulating Tumor Cells Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model